{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104940",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104940",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for phenprocoumon and VKORC1",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA450921",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA450921",
    "name" : "phenprocoumon"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA133787052",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA133787052",
    "symbol" : "VKORC1",
    "name" : "vitamin K epoxide reductase complex, subunit 1"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>For patients treated with phenprocoumon, consider checking INR more frequently in patients with the AA genotype at VKORC1 <a href=\"/rsid/rs9934438\">rs9934438</a>.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for phenprocoumon based on VKORC1 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They found that VKORC1 <a href=\"/rsid/rs9934438\">rs9934438</a> genotype contributes to dose variability.  However, they make no dosing recommendations at this time \"because of strict international normalized ratio monitoring by the Dutch Thrombosis Service.\"</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Genotype </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> VKORC1 <a href=\"/rsid/rs9934438\">rs9934438</a> AG </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5</td></tr><tr></tr><tr><td> VKORC1 <a href=\"/rsid/rs9934438\">rs9934438</a> AA </td><td> Check INR more frequently. </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms , &lt;470 ms ); INR increase &lt; 4.5</td></tr><tr></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>S: statistically significant difference.</li></ul>"
}